The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55

Journal of Biological Chemistry

Volumn 287, Issue 53, 2012, Pages 44234-44248

  Kargl, Julia ^a   Balenga, Nariman ^a,c   Parzmair, Gerald P ^a   Brown, Andrew J ^b   Heinemann, Akos ^a   Waldhoer, Maria ^a,d  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d HAGEDORN RESEARCH INSTITUTE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTORS; CENTRAL NERVOUS SYSTEMS; CO-EXPRESSION; EXTRACELLULAR SIGNAL-REGULATED KINASE; FACTOR ACTIVATION; G-PROTEIN COUPLED RECEPTORS; HEK-293; HUMAN EMBRYONIC KIDNEYS; IN-VITRO; MEDIATED TRANSCRIPTION; NUCLEAR FACTOR OF ACTIVATED T-CELLS; NUCLEAR FACTORS; PATHOPHYSIOLOGICAL; SERUM RESPONSE ELEMENTS; SIDE EFFECT; SIGNALING PATHWAYS; T CELL ACTIVATION; TRANSMEMBRANES;

COMMERCE; CYTOLOGY; HISTOLOGY; PIGMENTS; TISSUE; TRANSCRIPTION FACTORS;

CELLS;

CANNABINOID 1 RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL FUNCTION; EMBRYO; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SERUM RESPONSIVE ELEMENT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

CANNABINOIDS; DIMERIZATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; LYSOPHOSPHOLIPIDS; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84871793022     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.364109     Document Type: Article

References (66)

1. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564
2. Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (Pubitemid 23305569)
3. 2. Pharmacol. Rev. 62, 588-631
4. Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., and Walker, J. M. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393-411 (Pubitemid 28062631)
5. Buckley, N. E. (2008) The peripheral cannabinoid receptor knockout mice. An update. Br. J. Pharmacol. 153, 309-318
6. Balenga, N. A., Aflaki, E., Kargl, J., Platzer, W., Schröder, R., Blättermann, S., Kostenis, E., Brown, A. J., Heinemann, A., and Waldhoer, M. (2011) GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. 21, 1452-1469
7. Henstridge, C. M., Balenga, N. A., Kargl, J., Andradas, C., Brown, A. J., Irving, A., Sanchez, C., and Waldhoer, M. (2011) Minireview. Recent developments in the physiology and pathology of the lysophosphatidylinositol- sensitive receptor GPR55. Mol. Endocrinol. 25, 1835-1848
8. Pietr, M., Kozela, E., Levy, R., Rimmerman, N., Lin, Y. H., Stella, N., Vogel, Z., and Juknat, A. (2009) Differential changes in GPR55 during microglial cell activation. FEBS Lett. 583, 2071-2076
9. Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N. O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., and Greasley, P. J. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092-1101 (Pubitemid 350166046)
10. Sawzdargo, M., Nguyen, T., Lee, D. K., Lynch, K. R., Cheng, R., Heng, H. H., George, S. R., and O'Dowd, B. F. (1999) Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53, and GPR55. GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res. 64, 193-198 (Pubitemid 29052470)
11. 2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J. Cell Sci. 121, 1704-1717
12. Andradas, C., Caffarel, M. M., Pérez-Gómez, E., Salazar, M., Lorente, M., Velasco, G., Guzmán, M., and Sánchez, C. (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30, 245-252
13. Ford, L. A., Roelofs, A. J., Anavi-Goffer, S., Mowat, L., Simpson, D. G., Irving, A. J., Rogers, M. J., Rajnicek, A. M., and Ross, R. A. (2010) A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br. J. Pharmacol. 160, 762-771
14. Huang, L., Ramirez, J. C., Frampton, G. A., Golden, L. E., Quinn, M. A., Pae, H. Y., Horvat, D., Liang, L. J., and DeMorrow, S. (2011) Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab. Invest. 91, 1007-1017
15. Piñeiro, R., Maffucci, T., and Falasca, M. (2011) The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30, 142-152
16. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161-202 (Pubitemid 34575709)
17. Howlett, A. C. (2005) Cannabinoid receptor signaling. Handb. Exp. Pharmacol. 168, 53-79
18. Lauckner, J. E., Jensen, J. B., Chen, H. Y., Lu, H. C., Hille, B., and Mackie, K. (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A. 105, 2699-2704 (Pubitemid 351520576)
19. Sharir, H., and Abood, M. E. (2010) Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther. 126, 301-313
20. Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., Ross, R. A., and Rogers, M. J. (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. U.S.A. 106, 16511-16516
21. 2+ signaling and NFAT activation. FASEB J. 23, 183-193
22. Henstridge, C. M., Balenga, N. A., Schröder, R., Kargl, J. K., Platzer, W., Martini, L., Arthur, S., Penman, J., Whistler, J. L., Kostenis, E., Waldhoer, M., and Irving, A. J. (2010) GPR55 ligands promote receptor coupling to multiple signalling pathways. Br. J. Pharmacol. 160, 604-614
23. Schröder, R., Schmidt, J., Blättermann, S., Peters, L., Janssen, N., Grundmann, M., Seemann, W., Kaufel, D., Merten, N., Drewke, C., Gomeza, J., Milligan, G., Mohr, K., and Kostenis, E. (2011) Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat. Protoc. 6, 1748-1760
24. Brown, A. J., Daniels, D. A., Kassim, M., Brown, S., Haslam, C. P., Terrell, V. R., Brown, J., Nichols, P. L., Staton, P. C., Wise, A., and Dowell, S. J. (2011) Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J. Pharmacol. Exp. Ther. 337, 236-246
25. Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., and Sugiura, T. (2007) Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 362, 928-934 (Pubitemid 47390663)
26. Oka, S., Kimura, S., Toshida, T., Ota, R., Yamashita, A., and Sugiura, T. (2010) Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J. Biochem. 147, 671-678
27. 13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly. J. Biol. Chem. 270, 24631-24634
28. 12 subfamily of heterotrimeric G proteins. Growth, migration, and metastasis. Biochemistry 46, 6677-6687
29. Pertwee, R. G. (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129-180
30. Milligan, G., Bond, R. A., and Lee, M. (1995) Inverse agonism. Pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 16, 10-13
31. Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., and Caput, D. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244 (Pubitemid 24268029)
32. Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., and Astrup, A. (2007) Efficacy and safety of the weight-loss drug rimonabant. A meta-analysis of randomized trials. Lancet 370, 1706-1713 (Pubitemid 350100788)
33. Kapur, A., Zhao, P., Sharir, H., Bai, Y., Caron, M. G., Barak, L. S., and Abood, M. E. (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem. 284, 29817-29827
34. Heynen-Genel, S., Dahl, R., Shi, S., Milan, L., Hariharan, S., Sergienko, E., Hedrick, M., Dad, S., Stonich, D., Su, Y., Vicchiarelli, M., Mangravita-Novo, A., Smith, L. H., Chung, T. D. Y., Sharir, H., Caron, M. G., Barak, L. S., and Abood, M. E. (2010) Probe Reports from the NIH Molecular Libraries Program [Internet]. National Center for Biotechnology Information, Bethesda, MD
35. Kotsikorou, E., Madrigal, K. E., Hurst, D. P., Sharir, H., Lynch, D. L., Heynen-Genel, S., Milan, L. B., Chung, T. D., Seltzman, H. H., Bai, Y., Caron, M. G., Barak, L., Abood, M. E., and Reggio, P. H. (2011) Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 50, 5633-5647
36. Ferré, S., Baler, R., Bouvier, M., Caron, M. G., Devi, L. A., Durroux, T., Fuxe, K., George, S. R., Javitch, J. A., Lohse, M. J., Mackie, K., Milligan, G., Pfleger, K. D., Pin, J. P., Volkow, N. D., Waldhoer, M., Woods, A. S., and Franco, R. (2009) Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol. 5, 131-134
37. Ferré, S., Navarro, G., Casadó, V., Cortés, A., Mallol, J., Canela, E. I., Lluís, C., and Franco, R. (2010) G protein-coupled receptor heteromers as new targets for drug development. Prog. Mol. Biol. Transl. Sci. 91, 41-52
38. Bouvier, M. (2001) Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2, 274-286
39. Prinster, S. C., Hague, C., and Hall, R. A. (2005) Heterodimerization of G protein-coupled receptors. Specificity and functional significance. Pharmacol. Rev. 57, 289-298 (Pubitemid 41196951)
40. Waldhoer, M., Bofill-Cardona, E., Milligan, G., Freissmuth, M., and Nanoff, C. (1998) Differential uncoupling of A1 adenosine and D2 dopamine receptors by suramin and didemethylated suramin (NF037). Mol. Pharmacol. 53, 808-818 (Pubitemid 28244067)
41. Waldhoer, M., Fong, J., Jones, R. M., Lunzer, M. M., Sharma, S. K., Kostenis, E., Portoghese, P. S., and Whistler, J. L. (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U.S.A. 102, 9050-9055 (Pubitemid 40881076)
42. Wager-Miller, J., Westenbroek, R., and Mackie, K. (2002) Dimerization of G protein-coupled receptors. CB1 cannabinoid receptors as an example. Chem. Phys. Lipids 121, 83-89 (Pubitemid 36044545)
43. Kearn, C. S., Blake-Palmer, K., Daniel, E., Mackie, K., and Glass, M. (2005) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation. A mechanism for receptor cross-talk? Mol. Pharmacol. 67, 1697-1704 (Pubitemid 40594170)
44. Ellis, J., Pediani, J. D., Canals, M., Milasta, S., and Milligan, G. (2006) Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J. Biol. Chem. 281, 38812-38824 (Pubitemid 46042008)
45. Carriba, P., Ortiz, O., Patkar, K., Justinova, Z., Stroik, J., Themann, A., Müller, C., Woods, A. S., Hope, B. T., Ciruela, F., Casadó, V., Canela, E. I., Lluis, C., Goldberg, S. R., Moratalla, R., Franco, R., and Ferré, S. (2007) Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32, 2249-2259 (Pubitemid 47587686)
46. Bradley, D. M., Branch, C. L., Brown, B. J., Chan, W. N., Coulton, S., Dean, A. W., Doyle, P. M., Evans, B., Gilpin, M. L., Gough, S. L., Macritchie, J. A., Marshall, H. R., Nash, D. J., Porter, R. A., and Stasi, L. P. (2006) World patent application WO2006094843 A1
47. Martini, L., Thompson, D., Kharazia, V., and Whistler, J. L. (2010) Differential regulation of behavioral tolerance to WIN55,212-2 by GASP1. Neuropsychopharmacology 35, 1363-1373
48. Tschische, P., Moser, E., Thompson, D., Vischer, H. F., Parzmair, G. P., Pommer, V., Platzer, W., Schwarzbraun, T., Schaider, H., Smit, M. J., Martini, L., Whistler, J. L., and Waldhoer, M. (2010) The G-protein coupled receptor associated sorting protein GASP-1 regulates the signalling and trafficking of the viral chemokine receptor US28. Traffic 11, 660-674
49. Kargl, J., Balenga, N. A., Platzer, W., Martini, L., Whistler, J. L., and Waldhoer, M. (2012) The GPCR-associated sorting protein 1 regulates ligand-induced down-regulation of GPR55. Br. J. Pharmacol. 165, 2611-2619
50. Lefkowitz, R. J., and Shenoy, S. K. (2005) Transduction of receptor signals by β-arrestins. Science 308, 512-517
51. Reiter, E., and Lefkowitz, R. J. (2006) GRKs and β-arrestins. Roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17, 159-165
52. Milan-Lobo, L., and Whistler, J. L. (2011) Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking. J. Pharmacol. Exp. Ther. 337, 868-875
53. Balenga, N. A., Henstridge, C. M., Kargl, J., and Waldhoer, M. (2011) Pharmacology, signaling and physiological relevance of the G protein-coupled receptor 55. Adv. Pharmacol. 62, 251-277
54. Jordan, B. A., and Devi, L. A. (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697-700 (Pubitemid 29289066)
55. AbdAlla, S., Lother, H., and Quitterer, U. (2000) AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407, 94-98
56. George, S. R., Fan, T., Xie, Z., Tse, R., Tam, V., Varghese, G., and O'Dowd, B. F. (2000) Oligomerization of μ- and δ-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275, 26128-26135
57. Gomes, I., Jordan, B. A., Gupta, A., Trapaidze, N., Nagy, V., and Devi, L. A. (2000) Heterodimerization of μ and δ opioid receptors. A role in opiate synergy. J. Neurosci. 20, RC110
58. Rocheville, M., Lange, D. C., Kumar, U., Patel, S. C., Patel, R. C., and Patel, Y. C. (2000) Receptors for dopamine and somatostatin. Formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157 (Pubitemid 30203051)
59. González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J., and Sealfon, S. C. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452, 93-97 (Pubitemid 351355090)
60. Jordan, B. A., Gomes, I., Rios, C., Filipovska, J., and Devi, L. A. (2003) Functional interactions between μ opioid and α2A-adrenergic receptors. Mol. Pharmacol. 64, 1317-1324 (Pubitemid 37532221)
61. Seifert, R., and Wenzel-Seifert, K. (2002) Constitutive activity of G-protein-coupled receptors. Cause of disease and common property of wildtype receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366, 381-416 (Pubitemid 35251788)
62. Hinrichsen, L., Meyerholz, A., Groos, S., and Ungewickell, E. J. (2006) Bending a membrane. How clathrin affects budding. Proc. Natl. Acad. Sci. U.S.A. 103, 8715-8720 (Pubitemid 43878085)
63. Wolfe, B. L., and Trejo, J. (2007) Clathrin-dependent mechanisms of G protein-coupled receptor endocytosis. Traffic 8, 462-470 (Pubitemid 46638559)
64. Sedej, M., Schröder, R., Bell, K., Platzer, W., Vukoja, A., Kostenis, E., Heinemann, A., and Waldhoer, M. (2012) D-type prostanoid receptor enhances the signaling of chemoattractant receptor-homologous molecule expressed on T(H)2 cells. J. Allergy Clin. Immunol. 129, 492-500
65. Rozenfeld, R., Bushlin, I., Gomes, I., Tzavaras, N., Gupta, A., Neves, S., Battini, L., Gusella, G. L., Lachmann, A., Ma'ayan, A., Blitzer, R. D., and Devi, L. A. (2012) Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS One 7, e29239
66. Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., Fulleylove, M., Lancaster, H. C., Smith, J. C., Bailey, L. T., Wise, A., Brown, A. J., Richardson, J. C., and Chessell, I. P. (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139, 225-236